Zhao 2006.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 68. Age: aripiprazole group: mean = (24.3 士 9.4) years; quetiapine group: 18‐51 years, mean = (26.7 ± 8.4) years. Gender: male and female History: aripiprazole group: mean = (23 土 13) months; quetiapine group: mean =(4. 5 ± 2.9) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day. Mean dose = not reported. N = 34. 2. Quetiapine: Dose range: 100‐750 mg/day. Mean dose = (465 ± 132) mg/day. N = 34.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 30%‐50%, no effect: < 30%). Mental state: PANSS total score. Unable to use ‐ Mental state: PANSS positive subscale score, PANSS negative subscale score, PANSS general psychogenic pathological subscale score.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete outcome data.
Selective reporting (reporting bias)	High risk	TESS score was measured, but not reported.
Other bias	Low risk	None obvious.